Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + QL1706 + Dacarbazine + Lenvatinib for Melanoma Liver Metastases
NCT07847359Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in melanoma, sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 48 months. Started Oct 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07847359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847359.